Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Delzicol is a prescription delayed-release mesalamine capsule containing 400 mg. It treats mildly to moderately active ulcerative colitis in patients age 5 and older and maintains ulcerative colitis remission in adults. Each capsule contains four coated 100 mg mesalamine tablets designed for delayed release.
read more about delzicol ...The exact mechanism of mesalamine is not fully defined and appears to be mainly topical in the colon. Mesalamine can reduce production of inflammatory arachidonic acid metabolites, including prostaglandins, within colonic tissue. This local anti-inflammatory activity helps control ulcerative colitis.
Delzicol treats mildly to moderately active ulcerative colitis in adults and children age 5 and older. It is also approved to maintain remission of ulcerative colitis in adults. Pediatric treatment uses weight-based dosing and is divided into two daily doses for six weeks.
Adults with active ulcerative colitis take 800 mg three times daily for six weeks. Pediatric patients age 5 and older use weight-based twice-daily dosing up to 2.4 g daily. Adult maintenance dosing is 1.6 g daily in two to four divided doses. Capsules can be taken with or without food.
Serious concerns include kidney impairment, acute intolerance syndrome, hypersensitivity reactions, liver failure, severe skin reactions, photosensitivity, and kidney stones. Kidney function is checked before treatment and periodically during therapy. Adequate fluid intake lowers the risk of mesalamine-containing kidney stones.
Delzicol treats active ulcerative colitis from age 5 and maintains remission in adults.
Adults take 800 mg three times daily for six weeks.
Yes. Patients unable to swallow the capsule can open it and swallow all four inner tablets whole.
Yes. Kidney function is checked before treatment and periodically during therapy.
DailyMed - DELZICOL (mesalamine) capsule, delayed release. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d047e43-60c5-4d32-bd5e-204dee863afd. Date Accessed September 24, 2026.
Mesalamine. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a688021.html. Date Accessed September 24, 2026.
Mesalamine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/5-aminosalicylic%20acid. Date Accessed September 24, 2026.
Mesalamine. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551714/. Date Accessed September 24, 2026.
Supplement Approval - DELZICOL (mesalamine) Delayed-Release Capsules. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/204412Orig1s015ltr.pdf. Date Accessed September 24, 2026.